Last reviewed · How we verify
NCT07291544
Management of Supraventricular Tachycardias in Children
trial testing Management of children with supraventricular tachycardias in Supraventricular Arrhythmias in 1,400 participants. Completed in 30 September 2025.
30 September 2025
Quick facts
| Lead sponsor | Paris Cardiovascular Research Center (Inserm U970) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,400 |
| Start date | 1 January 2000 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2025 |
Drugs / interventions tested
- Management of children with supraventricular tachycardias
Conditions studied
- Supraventricular Arrhythmias — all drugs for Supraventricular Arrhythmias →
- Children — all drugs for Children →
- Management — all drugs for Management →
Sponsor
Paris Cardiovascular Research Center (Inserm U970)
Who can join
Adults 0 to 18, any sex, with Supraventricular Arrhythmias or Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background Supraventricular tachycardias (SVTs) are the most common arrhythmic events in children, with an estimated incidence of 13 per 100,000 per year before the age of 18. Few large patient cohorts have been reported, as most published studies are single-center. Large-scale studies come from medico-administrative databases, which lack the granularity needed for detailed analysis of outcomes according to the therapies used and the type of SVT. Furthermore, although a large proportion of neonatal SVTs do not recur (spontaneous resolution of the accessory pathway), there are limited comparative data on the effectiveness of antiarrhythmic therapies specifically in children after the age of 1 year. Management therefore varies greatly, in part because current guidelines propose different therapeutic options based on low-level evidence. Objectives: * Describe the management of SVTs (antiarrhythmic therapies and catheter ablation) in children in France * Compare the effectiveness of different antiarrhythmic treatments according to age (\<1 year and \>1 year) and type of SVT * Analyze the incidence of adverse events and complications associated with antiarrhythmic treatments and catheter ablation
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07291544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Paris Cardiovascular Research Center (Inserm U970) trials
Trials by the same sponsor.
- NCT04205461 — Prospective Evaluation of Programmed Ventricular Stimulation Before Pulmonary Valve Replacement in Patients With Tetralo · unknown
- NCT04202796 — Catheter Ablation in Congenital Heart Disease: French National Prospective Registry · unknown
- NCT04842851 — Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle · completed
- NCT05349162 — Epicardial vs. Transvenous ICDs in Children · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07291544 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Paris Cardiovascular Research Center (Inserm U970)
- Last refreshed: 2 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07291544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing